Prevention of radiation induced dermatitis in cancer patients
Phase 3
Recruiting
- Conditions
- RadiodermatitisDermatitisBreast NeoplasmsHead and Neck NeoplasmsC17.800.174.826C17.800.174C04.588.180C04.588.443
- Registration Number
- RBR-92cts3
- Lead Sponsor
- niversidade de Brasília
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Being an adult, over the age of 18 years old; Owning diagnosis of breast cancer or head and neck cancer; Being first referred to the radiotherapy protocol; Have integrates skin to start radiotherapy.
Exclusion Criteria
Have presented anticipated reaction of hypersensitivity to chamomile or any plant of the family Asteraceae or Compositae.
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are targeted in RBR-92cts3 for preventing radiation-induced dermatitis in breast and head/neck cancer patients?
How does the intervention in RBR-92cts3 compare to standard-of-care topical agents like amifostine or emollients for radiodermatitis prevention?
Are there predictive biomarkers identified in phase III trials for radiodermatitis susceptibility in patients undergoing breast or head and neck radiotherapy?
What adverse events are associated with radiodermatitis prevention strategies in phase III oncology trials, and how are they managed?
What combination therapies or alternative interventions are being explored alongside radioprotective agents for dermatitis prevention in cancer patients?